Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CASP7 | P55210 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306227 | 0.82 | POLB (0.41) | POLBCASP6CYP2A6ALOX12CYP1A2 | |
| SCHEMBL903605 | 0.75 | AHR (0.46) | POLBCASP6CYP2A6ALOX12CYP1A2 | |
| SCHEMBL16779994 | 0.75 | AHR (0.46) | POLBCASP6CYP2A6ALOX12CYP1A2 | |
| SCHEMBL3557 | 0.74 | — | — | |
| SCHEMBL14458072 | 0.71 | AHR (0.54) | POLBCASP6CYP2A6ALOX12NQO2 | |
| SCHEMBL18159595 | 0.70 | MAPK1 (0.46) | POLBCASP6CYP2A6ALOX12CYP1A2 | |
| Anthracene SCHEMBL29352043 | 0.69 | CYP2A6 (0.64) | CYP2A6ALOX12CYP1A2ALDH1A1HSD17B10 | |
| Anthracene SCHEMBL5713429 | 0.69 | CYP2A6 (0.64) | CYP2A6ALOX12CYP1A2ALDH1A1HSD17B10 | |
| Anthracene SCHEMBL7703 | 0.69 | CYP2A6 (0.64) | CYP2A6ALOX12CYP1A2ALDH1A1HSD17B10 | |
| Anthracene SCHEMBL2833889 | 0.69 | CYP2A6 (0.64) | CYP2A6ALOX12CYP1A2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | claimed |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-12-04 | — | — | US | claimed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | claimed |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | claimed |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | claimed |
| EP-2794589-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794591-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2794590-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | Novartis AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | claimed |
| EP-1656355-A2 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | claimed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | POLB 1559/4885CASP6 369/4885CYP2A6 46/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | POLB 1559/4885CASP6 369/4885CYP2A6 46/4885 |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | POLB 2974/4885CASP6 205/4885CYP2A6 4001/4885 |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | POLB 2974/4885CASP6 205/4885CYP2A6 4001/4885 |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | POLB 2974/4885CASP6 205/4885CYP2A6 4001/4885 |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | POLB 2974/4885CASP6 205/4885CYP2A6 4001/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | POLB 762/4885CASP6 1108/4885CYP2A6 291/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | POLB 3001/4885CASP6 165/4885CYP2A6 4136/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | POLB 3504/4885CASP6 1058/4885CYP2A6 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.